{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:14:56Z","timestamp":1791357296421,"version":"4.3.1"},"reference-count":22,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2017,10,13]],"date-time":"2017-10-13T00:00:00Z","timestamp":1507852800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100008375","name":"Universit\u00e4t Basel","doi-asserted-by":"publisher","award":["DMS2297"],"award-info":[{"award-number":["DMS2297"]}],"id":[{"id":"10.13039\/100008375","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Epilepsia"],"published-print":{"date-parts":[[2017,12]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      Older antiepileptic drugs (\n                      <jats:styled-content style=\"fixed-case\">AEDs<\/jats:styled-content>\n                      ) are known to cause Stevens\u2010Johnson syndrome and toxic epidermal necrolysis (\n                      <jats:styled-content style=\"fixed-case\">SJS<\/jats:styled-content>\n                      \/\n                      <jats:styled-content style=\"fixed-case\">TEN<\/jats:styled-content>\n                      ). However, evidence for newer\n                      <jats:styled-content style=\"fixed-case\">AED<\/jats:styled-content>\n                      is sparse. We quantified risks of\n                      <jats:styled-content style=\"fixed-case\">SJS<\/jats:styled-content>\n                      \/\n                      <jats:styled-content style=\"fixed-case\">TEN<\/jats:styled-content>\n                      in association with use of all\n                      <jats:styled-content style=\"fixed-case\">AED<\/jats:styled-content>\n                      s in the United Kingdom.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In a matched case\u2010control study of 480 previously validated\n                      <jats:styled-content style=\"fixed-case\">SJS<\/jats:styled-content>\n                      \/\n                      <jats:styled-content style=\"fixed-case\">TEN<\/jats:styled-content>\n                      cases (1995\u20132013) we used conditional logistic regression to calculate odds ratios (\n                      <jats:styled-content style=\"fixed-case\">ORs<\/jats:styled-content>\n                      ) with 95% confidence intervals (\n                      <jats:styled-content style=\"fixed-case\">CIs<\/jats:styled-content>\n                      ), and calculated absolute risks of\n                      <jats:styled-content style=\"fixed-case\">SJS<\/jats:styled-content>\n                      \/\n                      <jats:styled-content style=\"fixed-case\">TEN<\/jats:styled-content>\n                      within separate cohorts of new users of 28\n                      <jats:styled-content style=\"fixed-case\">AED<\/jats:styled-content>\n                      s. We assessed causality between drugs and\n                      <jats:styled-content style=\"fixed-case\">SJS<\/jats:styled-content>\n                      \/\n                      <jats:styled-content style=\"fixed-case\">TEN<\/jats:styled-content>\n                      in each exposed case, using an adapted version of the algorithm of drug causality for epidermal necrolysis (\n                      <jats:styled-content style=\"fixed-case\">ALDEN<\/jats:styled-content>\n                      ) score.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We observed a strong association between\n                      <jats:styled-content style=\"fixed-case\">SJS<\/jats:styled-content>\n                      \/\n                      <jats:styled-content style=\"fixed-case\">TEN<\/jats:styled-content>\n                      and new use of carbamazepine (\n                      <jats:styled-content style=\"fixed-case\">OR<\/jats:styled-content>\n                      92.57, 95%\n                      <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>\n                      19.89\u2013\u221e), phenytoin (\n                      <jats:styled-content style=\"fixed-case\">OR<\/jats:styled-content>\n                      49.96, 95%\n                      <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>\n                      10.13\u2013\u221e), and lamotrigine (\n                      <jats:styled-content style=\"fixed-case\">OR<\/jats:styled-content>\n                      26.90, 95%\n                      <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>\n                      4.88\u2013\u221e), where causality, according to the\n                      <jats:styled-content style=\"fixed-case\">ALDEN<\/jats:styled-content>\n                      score, was very probable or probable for most exposed cases. Absolute risks for\n                      <jats:styled-content style=\"fixed-case\">SJS<\/jats:styled-content>\n                      \/\n                      <jats:styled-content style=\"fixed-case\">TEN<\/jats:styled-content>\n                      were highest for phenytoin (45.86 cases\/100,000 exposed), lamotrigine (44.17 cases\/100,000 exposed), and carbamazepine (20.38 cases\/100,000 exposed). Despite increased\n                      <jats:styled-content style=\"fixed-case\">OR<\/jats:styled-content>\n                      s for valproate (40,941 exposed), gabapentin (116,037 exposed), pregabalin (59,967 exposed), and clobazam (4,300 exposed),\n                      <jats:styled-content style=\"fixed-case\">ALDEN<\/jats:styled-content>\n                      suggested no causal association. There were no observed cases of\n                      <jats:styled-content style=\"fixed-case\">SJS<\/jats:styled-content>\n                      \/\n                      <jats:styled-content style=\"fixed-case\">TEN<\/jats:styled-content>\n                      among new users of levetiracetam (n\u00a0=\u00a096,77), clonazepam (n\u00a0=\u00a018,075), or topiramate (n\u00a0=\u00a011,307).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance<\/jats:title>\n                    <jats:p>\n                      The results of our study are consistent with those of previous studies of\n                      <jats:styled-content style=\"fixed-case\">SJS<\/jats:styled-content>\n                      \/\n                      <jats:styled-content style=\"fixed-case\">TEN<\/jats:styled-content>\n                      , which found increased risks of\n                      <jats:styled-content style=\"fixed-case\">SJS<\/jats:styled-content>\n                      \/\n                      <jats:styled-content style=\"fixed-case\">TEN<\/jats:styled-content>\n                      in new use of carbamazepine, phenytoin, and lamotrigine. Despite frequent use, no\n                      <jats:styled-content style=\"fixed-case\">ALDEN<\/jats:styled-content>\n                      \u2010score confirmed cases were observed in new users of valproate, gabapentin, pregabalin, levetiracetam, topiramate, or clonazepam.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/epi.13925","type":"journal-article","created":{"date-parts":[[2017,10,13]],"date-time":"2017-10-13T02:07:01Z","timestamp":1507860421000},"page":"2178-2185","source":"Crossref","is-referenced-by-count":64,"title":["The risk of Stevens\u2010Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptic drugs"],"prefix":"10.1111","volume":"58","author":[{"given":"Noel","family":"Frey","sequence":"first","affiliation":[{"name":"Basel Pharmacoepidemiology Unit Division of Clinical Pharmacy and Epidemiology Department of Pharmaceutical Sciences University of Basel Basel Switzerland"},{"name":"Hospital Pharmacy University Hospital Basel Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Bodmer","sequence":"additional","affiliation":[{"name":"Internal Medicine Cantonal Hospital Zug Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Bircher","sequence":"additional","affiliation":[{"name":"Allergology University Hospital Basel Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"R\u00fcegg","sequence":"additional","affiliation":[{"name":"Division of Clinical Neurophysiology University Hospital Basel Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan S.","family":"Jick","sequence":"additional","affiliation":[{"name":"Boston Collaborative Drug Surveillance Program Boston University Lexington Massachusetts U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph R.","family":"Meier","sequence":"additional","affiliation":[{"name":"Basel Pharmacoepidemiology Unit Division of Clinical Pharmacy and Epidemiology Department of Pharmaceutical Sciences University of Basel Basel Switzerland"},{"name":"Hospital Pharmacy University Hospital Basel Basel Switzerland"},{"name":"Boston Collaborative Drug Surveillance Program Boston University Lexington Massachusetts U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Spoendlin","sequence":"additional","affiliation":[{"name":"Basel Pharmacoepidemiology Unit Division of Clinical Pharmacy and Epidemiology Department of Pharmaceutical Sciences University of Basel Basel Switzerland"},{"name":"Hospital Pharmacy University Hospital Basel Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,10,13]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0b013e31821201ed"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1159\/000335627"},{"key":"e_1_2_9_4_1","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/ddg.12747","article-title":"Severe drug\u2010induced skin reactions: clinical features, diagnosis, etiology, and therapy","volume":"13","author":"Paulmann M","year":"2015","journal-title":"J Dtsch Dermatol Ges"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jid.5701033"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199512143332404"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)05418-X"},{"key":"e_1_2_9_8_1","first-page":"2732","article-title":"Spontaneous reporting of Stevens\u2010Johnson syndrome and toxic epidermal necrolysis associated with antiepileptic drugs","volume":"19","author":"Ordonez L","year":"2015","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"e_1_2_9_9_1","first-page":"155","article-title":"Stevens\u2010Johnson syndrome associated with gabapentin","volume":"105","author":"Gonzalez\u2010Sicilia L","year":"1998","journal-title":"Am J Med"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-199902000-00022"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2007.48"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/pde.12527"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4124"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyv098"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2009.03537.x"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2009.252"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000156354.20227.F0"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2006.01.030"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.2217\/pgs.10.77"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2017.01.031"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2014.922544"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S57409"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1177\/2042098613499791"}],"container-title":["Epilepsia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fepi.13925","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/epi.13925","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T14:51:22Z","timestamp":1695480682000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/epi.13925"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,13]]},"references-count":22,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["10.1111\/epi.13925"],"URL":"https:\/\/doi.org\/10.1111\/epi.13925","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.731989003.793553838","asserted-by":"object"}]},"ISSN":["0013-9580","1528-1167"],"issn-type":[{"value":"0013-9580","type":"print"},{"value":"1528-1167","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,13]]}}}